- Home
- CET vs NVAX Comparison
CET vs NVAX Comparison
Compare CET & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- NVAX
- Stock Information
- Founded
- CET 1929
- NVAX 1987
- Country
- CET United States
- NVAX United States
- Employees
- CET N/A
- NVAX N/A
- Industry
- CET Finance/Investors Services
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CET Finance
- NVAX Health Care
- Exchange
- CET Nasdaq
- NVAX Nasdaq
- Market Cap
- CET 1.3B
- NVAX 1.3B
- IPO Year
- CET N/A
- NVAX 1995
- Fundamental
- Price
- CET $42.47
- NVAX $6.00
- Analyst Decision
- CET
- NVAX Buy
- Analyst Count
- CET 0
- NVAX 6
- Target Price
- CET N/A
- NVAX $17.83
- AVG Volume (30 Days)
- CET 40.7K
- NVAX 6.0M
- Earning Date
- CET 01-01-0001
- NVAX 05-09-2025
- Dividend Yield
- CET 5.29%
- NVAX N/A
- EPS Growth
- CET 26.33
- NVAX N/A
- EPS
- CET 9.95
- NVAX N/A
- Revenue
- CET $23,698,535.00
- NVAX $682,162,000.00
- Revenue This Year
- CET N/A
- NVAX $1.07
- Revenue Next Year
- CET N/A
- NVAX N/A
- P/E Ratio
- CET $4.27
- NVAX N/A
- Revenue Growth
- CET 11.75
- NVAX N/A
- 52 Week Low
- CET $40.08
- NVAX $3.81
- 52 Week High
- CET $49.51
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- CET 39.57
- NVAX 41.41
- Support Level
- CET $42.21
- NVAX $5.01
- Resistance Level
- CET $44.51
- NVAX $6.58
- Average True Range (ATR)
- CET 1.68
- NVAX 0.65
- MACD
- CET 0.03
- NVAX 0.02
- Stochastic Oscillator
- CET 41.07
- NVAX 50.25
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.